EAACI Biologicals Guidelines-Recommendations for severe asthma

Ioana Agache; Cezmi A Akdis; Mubeccel Akdis; Giorgio Walter Canonica; Thomas Casale; Tomas Chivato; Jonathan Corren; Derek K Chu; Stefano Del Giacco; Thomas Eiwegger; Breda Flood; Davide Firinu; James E Gern; Eckard Hamelmann; Nicola Hanania; Irene Hernández-Martín; Rebeca Knibb; Mika Mäkelä; Parameswaran Nair; Liam O'Mahony; Nikolaos G Papadopoulos; Alberto Papi; Hae-Sim Park; Luis Pérez de Llano; Oliver Pfaar; Santiago Quirce; Joaquin Sastre; Mohamed Shamji; Jurgen Schwarze; Oscar Palomares; Marek Jutel

doi:10.1111/all.14425

EAACI Biologicals Guidelines-Recommendations for severe asthma

Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Derek K Chu, Stefano Del Giacco, Thomas Eiwegger, Breda Flood, Davide Firinu, James E Gern, Eckard Hamelmann, Nicola Hanania, Irene Hernández-Martín, Rebeca Knibb, Mika Mäkelä, Parameswaran Nair, Liam O'MahonyNikolaos G Papadopoulos, Alberto Papi, Hae-Sim Park, Luis Pérez de Llano, Oliver Pfaar, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Oscar Palomares, Marek Jutel

Research output: Journal article (peer-reviewed) › Journal article

189 Citations (Scopus)

Abstract

Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.

Original language	English
Pages (from-to)	14-44
Number of pages	31
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	76
Issue number	1
DOIs	https://doi.org/10.1111/all.14425
Publication status	Published - Jan 2021
Externally published	Yes

Keywords

Asthma/diagnosis
Cost-Benefit Analysis
Humans
Phenotype

Access to Document

10.1111/all.14425

Cite this

Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., Flood, B., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Hernández-Martín, I., Knibb, R., Mäkelä, M., Nair, P., ... Jutel, M. (2021). EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 76(1), 14-44. https://doi.org/10.1111/all.14425

@article{d622430c5f93496caeb4bbfc9e5e8d2d,

title = "EAACI Biologicals Guidelines-Recommendations for severe asthma",

abstract = "Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.",

keywords = "Asthma/diagnosis, Cost-Benefit Analysis, Humans, Phenotype",

author = "Ioana Agache and Akdis, {Cezmi A} and Mubeccel Akdis and Canonica, {Giorgio Walter} and Thomas Casale and Tomas Chivato and Jonathan Corren and Chu, {Derek K} and {Del Giacco}, Stefano and Thomas Eiwegger and Breda Flood and Davide Firinu and Gern, {James E} and Eckard Hamelmann and Nicola Hanania and Irene Hern{\'a}ndez-Mart{\'i}n and Rebeca Knibb and Mika M{\"a}kel{\"a} and Parameswaran Nair and Liam O'Mahony and Papadopoulos, {Nikolaos G} and Alberto Papi and Hae-Sim Park and {P{\'e}rez de Llano}, Luis and Oliver Pfaar and Santiago Quirce and Joaquin Sastre and Mohamed Shamji and Jurgen Schwarze and Oscar Palomares and Marek Jutel",

note = "Publisher Copyright: {\textcopyright} 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2021",

month = jan,

doi = "10.1111/all.14425",

language = "English",

volume = "76",

pages = "14--44",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

Agache, I, Akdis, CA, Akdis, M, Canonica, GW, Casale, T, Chivato, T, Corren, J, Chu, DK, Del Giacco, S, Eiwegger, T, Flood, B, Firinu, D, Gern, JE, Hamelmann, E, Hanania, N, Hernández-Martín, I, Knibb, R, Mäkelä, M, Nair, P, O'Mahony, L, Papadopoulos, NG, Papi, A, Park, H-S, Pérez de Llano, L, Pfaar, O, Quirce, S, Sastre, J, Shamji, M, Schwarze, J, Palomares, O & Jutel, M 2021, 'EAACI Biologicals Guidelines-Recommendations for severe asthma', Allergy: European Journal of Allergy and Clinical Immunology, vol. 76, no. 1, pp. 14-44. https://doi.org/10.1111/all.14425

TY - JOUR

T1 - EAACI Biologicals Guidelines-Recommendations for severe asthma

AU - Agache, Ioana

AU - Akdis, Cezmi A

AU - Akdis, Mubeccel

AU - Canonica, Giorgio Walter

AU - Casale, Thomas

AU - Chivato, Tomas

AU - Corren, Jonathan

AU - Chu, Derek K

AU - Del Giacco, Stefano

AU - Eiwegger, Thomas

AU - Flood, Breda

AU - Firinu, Davide

AU - Gern, James E

AU - Hamelmann, Eckard

AU - Hanania, Nicola

AU - Hernández-Martín, Irene

AU - Knibb, Rebeca

AU - Mäkelä, Mika

AU - Nair, Parameswaran

AU - O'Mahony, Liam

AU - Papadopoulos, Nikolaos G

AU - Papi, Alberto

AU - Park, Hae-Sim

AU - Pérez de Llano, Luis

AU - Pfaar, Oliver

AU - Quirce, Santiago

AU - Sastre, Joaquin

AU - Shamji, Mohamed

AU - Schwarze, Jurgen

AU - Palomares, Oscar

AU - Jutel, Marek

PY - 2021/1

Y1 - 2021/1

N2 - Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.

AB - Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.

KW - Asthma/diagnosis

KW - Cost-Benefit Analysis

KW - Humans

KW - Phenotype

UR - http://www.scopus.com/inward/record.url?scp=85088928605&partnerID=8YFLogxK

U2 - 10.1111/all.14425

DO - 10.1111/all.14425

M3 - Journal article

C2 - 32484954

SN - 0105-4538

VL - 76

SP - 14

EP - 44

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 1

ER -

EAACI Biologicals Guidelines-Recommendations for severe asthma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this